Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2015-11-12
Target enrollment:
Participant gender:
Summary
This is a single center phase I trial designed to determine the maximum tolerated dose (MTD)
of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of
intraperitoneal (IP) delivery of haploidentical donor NK cells and IL-2 after a
non-myeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen for the treatment
of recurrent ovarian, fallopian tube, and primary peritoneal cancer.